Skip to main content

Featured

BoC Held Again at 2.25% — But a Rate Hike Is Now More Likely Than Not Before Year-End

  Bond markets put the odds of an October 28 hike at 57%. Here's what the big banks are forecasting, what it means for your mortgage payment, and how to think about your next move. MoneySavings.ca · September 17, 2026 The Bank of Canada kept its overnight rate at 2.25% on September 2 — the seventh consecutive hold since the last cut in October 2025. On the surface, nothing changed. Below the surface, everything did. Governor Tiff Macklem's post-decision language was the most hawkish the Bank has sounded in over a year. He flagged that persistently high oil prices (Brent has since touched $107) and new U.S. tariffs — combined with Canada's own $27.6 billion retaliation list — are creating genuine upside risks to inflation. The BoC's August deliberations summary, released September 16, confirmed the Governing Council is now actively weighing a hike, not just a hold. The August CPI reading that came in on September 14 didn't settle anything: headline inflation held at ...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment